ライフサイエンスコーパス: hyperinsulinemic

1 wing treatment protocols, all rats underwent hyperinsulinemic (0.2 units kg(-1) min(-1)), severe hypo

2 On the fourth day, rats were subjected to a hyperinsulinemic (0.2 units x kg(-1) x min(-1)) severe h

3 pups were glucose intolerant (P = 0.04) and hyperinsulinemic (1.3-fold increase, P = 0.02) by 1 mont

4 ded hypoglycemic (100, 70, 50, and 30 mg/dl) hyperinsulinemic (20 mU/kg/min) clamps and nonhypoglycem

5 360-600 min, the remaining dogs underwent a hyperinsulinemic (4x basal) hyperglycemic clamp (arteria

6 Day 1 consisted of either two 2-h hyperinsulinemic (812 +/- 50 pmol/L)-euglycemic (5 +/- 0

7 50 pmol/L)-euglycemic (5 +/- 0.1 mmol/L) or hyperinsulinemic (812 +/- 50 pmol/L)-hypoglycemic (2.9 +

8 Day 1 consisted of morning and afternoon 2-h hyperinsulinemic- (9 pmol x kg(-1) x min(-1)) euglycemic

9 al diet had reduced perigonadal fat but were hyperinsulinemic and by age 12 months, were insulin defi

10 insulin receptor substrate-1 (IRS1-het) are hyperinsulinemic and insulin resistant during pregnancy,

11 ably, obese patients with MC4R mutations are hyperinsulinemic and resistant to obesity-induced hypert

12 sed CB(1) specifically in hepatocytes became hyperinsulinemic as a result of reduced insulin clearanc

13 ctose but in the presence of a hyperglycemic-hyperinsulinemic challenge including portal vein glucose

14 SI was measured using euglycemic-hyperinsulinemic clamp (EGC), before (week 0 [w0]) and a

15 Euglycemic-hyperinsulinemic clamp (EHC) was preformed to assess the

16 before and 1 month after RYGB by euglycemic hyperinsulinemic clamp (EHC), by intravenous glucose tol

17 dilution, insulin sensitivity by euglycemic-hyperinsulinemic clamp (steady-state glucose utilization

18 Here we show that initiation of a euglycemic-hyperinsulinemic clamp 4 h after single-legged exercise

19 During a postprandial hyperglycemic-hyperinsulinemic clamp after SGLT2-I treatment, E-Rd inc

20 Insulin sensitivity (S(I)) was assessed by hyperinsulinemic clamp and lean body mass (LBM) and tota

21 A euglycemic-hyperinsulinemic clamp and skeletal muscle biopsies were

22 , or glucose disposal rates under euglycemic hyperinsulinemic clamp conditions (SMD: 0.00; 95% CI: 20

23 se homeostasis was assessed using euglycemic-hyperinsulinemic clamp coupled with tracer radioactively

24 sue in overweight subjects who had undergone hyperinsulinemic clamp experiments.

25 However, the hyperinsulinemic clamp increased brain glucose metabolis

26 ds to assess resistance are available (e.g., hyperinsulinemic clamp or minimal model), but surrogate

27 od before the initiation of the hypoglycemic-hyperinsulinemic clamp protocol and during the last 30 m

28 Euglycemic-hyperinsulinemic clamp studies confirmed the marked impr

29 Euglycemic-hyperinsulinemic clamp studies demonstrate that deletion

30 Euglycemic, hyperinsulinemic clamp studies indicated RYGB improved t

31 as similar to that in control muscles during hyperinsulinemic clamp studies.

32 was increased during fasting but not during hyperinsulinemic clamp studies.

33 before (basal period) and during euglycemic-hyperinsulinemic clamp studies.

34 n synthesis compared with WT controls during hyperinsulinemic clamp studies.

35 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique.

36 conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity a

37 her saline infusion (sham) or an isoglycemic-hyperinsulinemic clamp using B28-Asp-insulin (which can

38 A hyperglycemic-hyperinsulinemic clamp was established in the presence o

39 igitorum longus muscle during the euglycemic-hyperinsulinemic clamp was increased in lean gamma3(R225

40 y and muscle insulin sensitivity (euglycemic-hyperinsulinemic clamp with 2-deoxyglucose) and fat util

41 , muscle, and adipose tissue by a euglycemic hyperinsulinemic clamp with 3-(3)H-glucose.

42 tabolism (insulin tolerance test, euglycemic-hyperinsulinemic clamp, and hepatic expression of genes

43 sulin sensitivity was analyzed by euglycemic-hyperinsulinemic clamp, and molecular tools were used to

44 A euglycemic-hyperinsulinemic clamp, muscle biopsy specimens, and mag

45 atients at risk for CIM underwent euglycemic-hyperinsulinemic clamp, muscle microdialysis studies, an

46 During the hyperinsulinemic clamp, the glucose infusion rate (GIR)

47 During euglycemic-hyperinsulinemic clamp, there is no suppression of hepat

48 ssociation of genetic scores with euglycemic-hyperinsulinemic clamp- and oral glucose tolerance test-

49 n resistance, as verified using a euglycemic/hyperinsulinemic clamp.

50 sitivity was quantitated with the euglycemic-hyperinsulinemic clamp.

51 glucose production as assessed by euglycemic hyperinsulinemic clamp.

52 e conditions and during a hyperaminoacidemic-hyperinsulinemic clamp.

53 lucose tolerance test (IVGTT) and euglycemic-hyperinsulinemic clamp.

54 labeled C-peptide, increased modestly during hyperinsulinemic clamp.

55 uction is impaired as assessed by euglycemic-hyperinsulinemic clamp.

56 obtained before and after 8-h hyperglycemic-hyperinsulinemic clamping in 13 normal subjects and in 6

57 Subjects were also studied by euglycemic-hyperinsulinemic clamps performed at rest and 3 h after

58 rticipants without diabetes underwent paired hyperinsulinemic clamps separated by 4 weeks.

59 pre- and 3 months post-RYGB, and euglycemic-hyperinsulinemic clamps were used to assess insulin sens

60 ree different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GI

61 sensitivity, as measured by using euglycemic-hyperinsulinemic clamps with infusion of [6,6-(2)H(2)]gl

62 rs with DM and 19 control subjects underwent hyperinsulinemic clamps with maintained sequential hyper

63 ed glucose uptake measured during euglycemic-hyperinsulinemic clamps, suggesting a role of beige cell

64 c (5.0 mmol/L) and hypoglycemic (2.8 mmol/L) hyperinsulinemic clamps, we compared brain activation re

65 oral glucose tolerance tests and euglycemic-hyperinsulinemic clamps.

66 eripheral insulin resistance, they were less hyperinsulinemic during a glucose tolerance test because

67 insulinemic hypoglycemia (bolus insulin), 2) hyperinsulinemic euglycemia (bolus insulin and glucose i

68 nsulinemic clamps with maintained sequential hyperinsulinemic euglycemia (plasma glucose, 90 mg/dL [5

69 eline, the subsequent changes in MBFR during hyperinsulinemic euglycemia and hyperinsulinemic hypogly

70 e dipyridamole stress at baseline and during hyperinsulinemic euglycemia and hyperinsulinemic hypogly

71 In control subjects, MBFR increased during hyperinsulinemic euglycemia by 0.57 U (22%) above baseli

72 onsisted of either morning and afternoon 2-h hyperinsulinemic euglycemia or 2-h hyperinsulinemic hypo

73 espectively, (all P < 0.01) during zinc-free hyperinsulinemic euglycemia over the first 60 min.

74 Hyperinsulinemic euglycemic (5 mmol/L) and hypoglycemic

75 ight fast, all subjects underwent a two-step hyperinsulinemic euglycemic (5.0 mmol/L)-hypoglycemic (2

76 Day 1 involved hyperinsulinemic euglycemic (90 mg/dL x 1 h), then hypog

77 ealthy non-diabetic participants underwent a hyperinsulinemic euglycemic (92+/-3 mg/dL) - hypoglycemi

78 For this purpose, hyperinsulinemic euglycemic and hypoglycemic glucose cla

79 resonance (MR) imaging system combined with hyperinsulinemic euglycemic clamp (HEC) was used.

80 were assessed with a 40-mU x m(-2) x min(-1) hyperinsulinemic euglycemic clamp combined with a [6,6-(

81 ,3,3-(2)H(5)]glycerol, in combination with a hyperinsulinemic euglycemic clamp during the last 3 hrs.

82 taken from both legs before and after a 3-h hyperinsulinemic euglycemic clamp performed 3 h after a

83 ulin sensitivity was determined by using the hyperinsulinemic euglycemic clamp procedure.

84 Gene expression analyses and hyperinsulinemic euglycemic clamp results suggest that C

85 ion and glucose clearance were quantified by hyperinsulinemic euglycemic clamp studies and pyruvate t

86 However, hyperinsulinemic euglycemic clamp studies revealed impro

87 Furthermore, hyperinsulinemic euglycemic clamp studies showed no diff

88 Hyperinsulinemic euglycemic clamp studies showed that th

89 enhanced systemic insulin sensitivity during hyperinsulinemic euglycemic clamp studies.

90 A hyperinsulinemic euglycemic clamp was used to compare ti

91 raphy), insulin sensitivity (measured with a hyperinsulinemic euglycemic clamp with [6,6-(2)H(2)]-glu

92 aging (MRI), and insulin sensitivity using a hyperinsulinemic euglycemic clamp with a glucose isotope

93 o metabolic (oral glucose tolerance test and hyperinsulinemic euglycemic clamp) and imaging studies (

94 of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before

95 R or RES training on insulin sensitivity (by hyperinsulinemic euglycemic clamp), body composition (by

96 etion pattern between a baseline study and a hyperinsulinemic euglycemic clamp.

97 This finding was confirmed with the use of hyperinsulinemic euglycemic clamping, showing a glucose

98 Hyperinsulinemic euglycemic clamps were performed to det

99 unctional MRI (fMRI) combined with a stepped hyperinsulinemic euglycemic-hypoglycemic clamp and behav

100 rculating insulin and glucose levels through hyperinsulinemic, euglycemic clamp studies.

101 insulin sensitivity were assessed using the hyperinsulinemic- euglycemic clamp combined with the glu

102 cells (PBMCs) and monocytes obtained during hyperinsulinemic-euglycemic (5.0 mmol/L)-hypoglycemic (2

103 -(13)C]glucose over 22-54 h after undergoing hyperinsulinemic-euglycemic (glucose concentration 92.4

104 Hyperglycemic (HG) and hyperinsulinemic-euglycemic (HI) clamps were performed t

105 We assessed glucose homeostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp stud

106 nsulin-sensitive (IS; n = 10), determined by hyperinsulinemic-euglycemic clamp (>30% greater in IS co

107 Insulin action was measured by a three-stage hyperinsulinemic-euglycemic clamp (4, 8, and 40 mU/m(2)/

108 centration 57.2 +/- 9.7 mg/dl) than during a hyperinsulinemic-euglycemic clamp (95.3 +/- 3.3 mg/dl),

109 Twenty-three patients underwent a two-step hyperinsulinemic-euglycemic clamp (HEC) with glucose tra

110 full-heritage Pima Indians (P = 0.027) or a hyperinsulinemic-euglycemic clamp among 536 nondiabetic

111 Hyperinsulinemic-euglycemic clamp analysis 8 weeks after

112 Female mice were assessed by hyperinsulinemic-euglycemic clamp analysis and indirect

113 Hyperinsulinemic-euglycemic clamp analysis was used to a

114 ndrial function in type 1 diabetes using the hyperinsulinemic-euglycemic clamp and (31)P-MRS before,

115 tivity and secretion were evaluated by a 3-h hyperinsulinemic-euglycemic clamp and a 2-h hyperglycemi

116 Assessments by hyperinsulinemic-euglycemic clamp and a glucose toleranc

117 beginning and end of each dietary period, a hyperinsulinemic-euglycemic clamp and an intravenous glu

118 Insulin sensitivity was measured by hyperinsulinemic-euglycemic clamp and insulin secretion

119 e, and secretion and glucose tolerance using hyperinsulinemic-euglycemic clamp and intravenous and or

120 cose tolerance and insulin sensitivity using hyperinsulinemic-euglycemic clamp and muscle insulin rec

121 cTg mice were highly insulin sensitive under hyperinsulinemic-euglycemic clamp conditions, eliminatin

122 The hyperinsulinemic-euglycemic clamp experiment showed that

123 Hyperinsulinemic-euglycemic clamp experiments show, for

124 olerance tests, insulin tolerance tests, and hyperinsulinemic-euglycemic clamp experiments.

125 ion (r = 0.31, P < 0.05) and negatively with hyperinsulinemic-euglycemic clamp glucose infusion rate

126 body glucose metabolism, as assessed during hyperinsulinemic-euglycemic clamp in awake mice.

127 In addition, infusion of insulin during a hyperinsulinemic-euglycemic clamp induced conspicuous ER

128 ipheral insulin sensitivity, measured by the hyperinsulinemic-euglycemic clamp method.

129 During hyperinsulinemic-euglycemic clamp of diabetic KKA(Y) mic

130 rations, under basal conditions and during a hyperinsulinemic-euglycemic clamp procedure (HECP), with

131 d after treatment was evaluated by using the hyperinsulinemic-euglycemic clamp procedure in conjuncti

132 A two-stage hyperinsulinemic-euglycemic clamp procedure in conjuncti

133 473), and p-AKT(Thr308) in 22 women during a hyperinsulinemic-euglycemic clamp procedure with and wit

134 rcentage increase in glucose uptake during a hyperinsulinemic-euglycemic clamp procedure).

135 A hyperinsulinemic-euglycemic clamp procedure, in conjunct

136 The hyperinsulinemic-euglycemic clamp revealed that hepatic

137 Hyperinsulinemic-euglycemic clamp reveals an increased g

138 Hyperinsulinemic-euglycemic clamp studies demonstrated t

139 e, insulin, and pyruvate tolerance tests and hyperinsulinemic-euglycemic clamp studies established in

140 Hyperinsulinemic-euglycemic clamp studies indicate that

141 Hyperinsulinemic-euglycemic clamp studies reveal that th

142 Hyperinsulinemic-euglycemic clamp studies revealed great

143 Hyperinsulinemic-euglycemic clamp studies revealed signi

144 glucose homeostasis on a high-fat diet, and hyperinsulinemic-euglycemic clamp studies revealed that

145 Hyperinsulinemic-euglycemic clamp studies revealed that

146 Hyperinsulinemic-euglycemic clamp studies showed that ad

147 Hyperinsulinemic-euglycemic clamp studies suggest that D

148 ize, glucose and insulin tolerance tests and hyperinsulinemic-euglycemic clamp studies were performed

149 iled 364 biopsies harvested before and after hyperinsulinemic-euglycemic clamp studies, at baseline a

150 increased hepatic insulin sensitivity during hyperinsulinemic-euglycemic clamp studies, which was ass

151 vity in 26 diabetic subjects was assessed by hyperinsulinemic-euglycemic clamp studies.

152 cific insulin sensitivity were determined by hyperinsulinemic-euglycemic clamp studies.

153 Glucose metabolism was investigated by hyperinsulinemic-euglycemic clamp studies.

154 In addition, a hyperinsulinemic-euglycemic clamp suggests that intracer

155 Improvement was assessed by using the hyperinsulinemic-euglycemic clamp technique.

156 VN, in combination with isotope dilution and hyperinsulinemic-euglycemic clamp techniques.

157 sion rate was increased more than 30% in the hyperinsulinemic-euglycemic clamp test.

158 us of amino acids was administered and a 3-h hyperinsulinemic-euglycemic clamp was commenced ("fed" p

159 The glucose infusion rate during a hyperinsulinemic-euglycemic clamp was increased by 50% i

160 n sensitivity in Wistar rats assessed by the hyperinsulinemic-euglycemic clamp was minimally affected

161 During the last 2 h, a hyperinsulinemic-euglycemic clamp was performed.

162 ecific insulin sensitivity was assessed by a hyperinsulinemic-euglycemic clamp with [6,6-(2)H2]-gluco

163 e SAs and 12 matched Cs underwent a two-step hyperinsulinemic-euglycemic clamp with skeletal muscle b

164 epatic insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tr

165 tests (OGTTs), graded glucose infusion, and hyperinsulinemic-euglycemic clamp with stable-isotope-la

166 ssion: with and without insulin stimulation (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeox

167 a], [(2)H5]glycerol at baseline and during a hyperinsulinemic-euglycemic clamp), lipid oxidation (ind

168 ences in insulin sensitivity, as measured by hyperinsulinemic-euglycemic clamp, and skeletal muscle m

169 Insulin sensitivity was measured by a hyperinsulinemic-euglycemic clamp, and skeletal muscle m

170 During the hyperinsulinemic-euglycemic clamp, retrodialysis of dexa

171 -fold more insulin sensitive, as measured by hyperinsulinemic-euglycemic clamp, than C57BL/6 wild-typ

172 and BMI-matched controls (n = 6) underwent a hyperinsulinemic-euglycemic clamp, VO2max test, dual-ene

173 ere hepatic insulin resistance assessed by a hyperinsulinemic-euglycemic clamp, which could mostly be

174 whole-body and leg glucose disposal during a hyperinsulinemic-euglycemic clamp, while decreasing hepa

175 and augments muscle glucose uptake during a hyperinsulinemic-euglycemic clamp.

176 of endogenous glucose production during the hyperinsulinemic-euglycemic clamp.

177 ted with insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp.

178 study comprised a 5-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.

179 atheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.

180 opsied skeletal muscles at the baseline of a hyperinsulinemic-euglycemic clamp.

181 small animal PET system was performed under hyperinsulinemic-euglycemic clamp.

182 Insulin resistance was assessed by a hyperinsulinemic-euglycemic clamp.

183 In vivo glucose metabolism was evaluated by hyperinsulinemic-euglycemic clamp.

184 on lower rates of glucose infusion during a hyperinsulinemic-euglycemic clamp.

185 r muscle [(3)H]-2-deoxyglucose uptake during hyperinsulinemic-euglycemic clamp.

186 o suppress hepatic glucose production during hyperinsulinemic-euglycemic clamp.

187 s 30% higher than that of the WT mice in the hyperinsulinemic-euglycemic clamp.

188 letal muscle glucose uptake as measured by a hyperinsulinemic-euglycemic clamp.

189 pearance, and muscle glucose uptake during a hyperinsulinemic-euglycemic clamp.

190 ody insulin sensitivity was measured using a hyperinsulinemic-euglycemic clamp.

191 r intralipid/heparin-infusion (high FFA) and hyperinsulinemic-euglycemic clamping (low FFA) in a rand

192 Hyperinsulinemic-euglycemic clamping studies revealed th

193 ects underwent studies comparing fasting and hyperinsulinemic-euglycemic clamping with tracer infusio

194 IL-10 (M(IL10)) and in wild-type mice during hyperinsulinemic-euglycemic clamping.

195 nt-infusion administration of tracers during hyperinsulinemic-euglycemic clamping.

196 Hyperinsulinemic-euglycemic clamps and insulin tolerance

197 Hyperinsulinemic-euglycemic clamps and signaling studies

198 nd women underwent research tests, including hyperinsulinemic-euglycemic clamps and vastus lateralis

199 er day) or vehicle treatment, mice underwent hyperinsulinemic-euglycemic clamps combined with radiola

200 Hyperinsulinemic-euglycemic clamps confirmed enhanced in

201 and insulin sensitivity was determined using hyperinsulinemic-euglycemic clamps in conscious mice.

202 Hyperinsulinemic-euglycemic clamps in DIO mice revealed

203 ity using glucose tolerance tests (GTTs) and hyperinsulinemic-euglycemic clamps in mouse models of ty

204 integrin interaction in IR was studied using hyperinsulinemic-euglycemic clamps on integrin alpha(2)b

205 involved one of the following: 1) two 90-min hyperinsulinemic-euglycemic clamps plus naloxone infusio

206 Hyperinsulinemic-euglycemic clamps revealed no differenc

207 a, investigation of insulin resistance using hyperinsulinemic-euglycemic clamps revealed no significa

208 We used hyperinsulinemic-euglycemic clamps to show a bona fide c

209 ance spectroscopy to assess IMCL content and hyperinsulinemic-euglycemic clamps using [6,6-(2)H(2)] g

210 etabolic profile, and insulin sensitivity by hyperinsulinemic-euglycemic clamps were examined.

211 s and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were performed to ass

212 Hyperinsulinemic-euglycemic clamps were used to assess i

213 uced by dietary methionine restriction (MR), hyperinsulinemic-euglycemic clamps were used to examine

214 ivity using acute insulin administration and hyperinsulinemic-euglycemic clamps with [(3)H]glucose in

215 First, we performed hyperinsulinemic-euglycemic clamps with concurrent hippo

216 Twenty-one men underwent two hyperinsulinemic-euglycemic clamps with d-[6,6-(2)H2]glu

217 s naloxone infusion (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60%

218 ped hyperinsulinemic-hypoglycemic and paired hyperinsulinemic-euglycemic clamps with infusion of 6,6-

219 tic resonance spectroscopy before and during hyperinsulinemic-euglycemic clamps with isotope dilution

220 ay absorptiometry), insulin sensitivity (via hyperinsulinemic-euglycemic clamps), and insulin secreti

221 Using direct measures (i.e., hyperinsulinemic-euglycemic clamps), we examined the rel

222 increased glucose disposal rate (measured by hyperinsulinemic-euglycemic clamps).

223 ased on glucose and insulin tolerance tests, hyperinsulinemic-euglycemic clamps, and insulin signalin

224 glucose production in isolated hepatocytes, hyperinsulinemic-euglycemic clamps, liver triglyceride c

225 Using hyperinsulinemic-euglycemic clamps, we studied insulin a

226 sing glucose and insulin tolerance tests and hyperinsulinemic-euglycemic clamps.

227 peritoneal glucose tolerance test and during hyperinsulinemic-euglycemic clamps.

228 specific insulin sensitivity was analyzed by hyperinsulinemic-euglycemic clamps.

229 eatine kisase (MCK)-DGAT1 transgenic mice by hyperinsulinemic-euglycemic clamps.

230 ivity (M value) was assessed with the use of hyperinsulinemic-euglycemic clamps.

231 Insulin sensitivity was assessed by hyperinsulinemic-euglycemic glucose clamp before and aft

232 A 2-stage hyperinsulinemic-euglycemic insulin clamp was used to me

233 Day 1 consisted of morning and afternoon 2-h hyperinsulinemic-euglycemic or hypoglycemic clamps with

234 In obese, hyperglycemic, hyperinsulinemic female Lepr(db/db) mice, GE was acceler

235 rmined systemic glucose uptake by euglycemic-hyperinsulinemic glucose clamp in 15 normal-weight and 1

236 mmol/L), and during recovery (5-6 mmol/L) by hyperinsulinemic glucose clamp.

237 -glucose positron emission tomography during hyperinsulinemic glucose clamps at nominal plasma glucos

238 asting plasma insulin <11.2 mU/L, n = 18) or hyperinsulinemic (HI) (fasting plasma insulin >11.2 mU/L

239 line (low insulin/sham clamp) or isoglycemic-hyperinsulinemic (high insulin) clamps using B28-Asp ins

240 ulinemic-euglycemic clamp) and postprandial (hyperinsulinemic hyperaminoacidemic-euglycemic clamp) co

241 uscle protein synthesis rates in response to hyperinsulinemic-hyperaminoacidemic clamps.

242 ct and store more glucose in the presence of hyperinsulinemic hyperglycemia later in the same day, in

243 To understand the fate of ICCs in hyperinsulinemic, hyperglycemic states characterized by

244 -fat and -fructose diet [P-HFF]) underwent a hyperinsulinemic-hyperglycemic clamp with intraportal gl

245 rnoon 2-h hyperinsulinemic euglycemia or 2-h hyperinsulinemic hypoglycemia (2.9 mmol/l) with either 1

246 examined on three randomized study days: 1) hyperinsulinemic hypoglycemia (bolus insulin), 2) hyperi

247 Hyperinsulinemic hypoglycemia (HI) and congenital polycy

248 Postprandial hyperinsulinemic hypoglycemia (PHH) is often reported af

249 glucose, 90 mg/dL [5.0 mmol/L]) followed by hyperinsulinemic hypoglycemia (plasma glucose, 50 mg/dL

250 0.38 to 0.75; P<0.0001) and decreased during hyperinsulinemic hypoglycemia by 0.36 U (14%) below base

251 -controlled cross-over trial using a stepped hyperinsulinemic hypoglycemia clamp was performed in 12

252 MBFR during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia in DM patients were simila

253 amplified, the counterregulatory response to hyperinsulinemic hypoglycemia in vivo.

254 Congenital hyperinsulinemic hypoglycemia is a group of genetic diso

255 Hyperinsulinemic hypoglycemia is the most common cause o

256 d in type 2 diabetes, neonatal diabetes, and hyperinsulinemic hypoglycemia of infancy (HHI).

257 gene associated with the disease persistent hyperinsulinemic hypoglycemia of infancy (PHHI).

258 oop variant and GCK variants associated with hyperinsulinemic hypoglycemia reveal two distinct mechan

259 -1 in postprandial glycemia in patients with hyperinsulinemic hypoglycemia syndrome after gastric byp

260 ibitor sirolimus in four infants with severe hyperinsulinemic hypoglycemia that had been unresponsive

261 The treatment of hyperinsulinemic hypoglycemia that is unresponsive to di

262 thase activity was completely ablated during hyperinsulinemic hypoglycemia, and catecholamine signali

263 ns causing monogenic diabetes and congenital hyperinsulinemic hypoglycemia.

264 roven in critically ill children at risk for hyperinsulinemic hypoglycemia.

265 receptor 1 (SUR1)/ABCC8 from a patient with hyperinsulinemic hypoglycemia.

266 e and during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia.

267 earched for relevant literature on exogenous hyperinsulinemic hypoglycemia.

268 can help guide the management of iatrogenic hyperinsulinemic hypoglycemia.

269 oss-over order on 5 patients with endogenous hyperinsulinemic hypoglycemia.

270 geted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduc

271 participants (n = 10 per group) underwent a hyperinsulinemic-hypoglycemic (2.6 mmol/L) clamp, either

272 lucose concentration 92.4 +/- 2.3 mg/dl) and hyperinsulinemic-hypoglycemic (52.9 +/- 4.8 mg/dl) clamp

273 ahepatic islet transplantation using stepped hyperinsulinemic-hypoglycemic and paired hyperinsulinemi

274 means +/- SD, P < 0.02, n = 5) during a 2-h hyperinsulinemic-hypoglycemic clamp (glucose concentrati

275 3 weeks (range 19-25) after GBP surgery with hyperinsulinemic-hypoglycemic clamp (stepwise to plasma

276 Day 2 consisted of a single-step hyperinsulinemic-hypoglycemic clamp of 2.9 mmol/l.

277 Subsequently, a hyperinsulinemic-hypoglycemic clamp study was performed.

278 Day 2 consisted of a single 2-h hyperinsulinemic-hypoglycemic clamp.

279 diaphragmatic vagotomy (TSV) were exposed to hyperinsulinemic-hypoglycemic clamps where glycemia was

280 On day 2, all were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone conc

281 sing a catecholamine-specific neurotoxin and hyperinsulinemic-hypoglycemic clamps, we found that symp

282 entrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chr

283 ) and decreased epinephrine secretion during hyperinsulinemic/hypoglycemic clamp in rats.

284 th no fructose infusion followed by a 2-hour hyperinsulinemic/hypoglycemic clamp.

285 imental approaches: 1) glucose gavage and 2) hyperinsulinemic intravenous infusion, for studies in ei

286 his DNA region was confirmed in the heart of hyperinsulinemic mice.

287 thotopic mammary tumors in control FVB/n and hyperinsulinemic MKR mice, and treated them with the ins

288 BEZ235 decreased mammary tumor growth in the hyperinsulinemic MKR mouse.

289 They underwent hyperinsulinemic-normoglycemic clamps with [6,6-(2)H2]gl

290 In fed and in hyperinsulinemic obese mice, insulin signalling leads to

291 y, Tregs from the visceral adipose tissue of hyperinsulinemic, obese mice showed a similar specific d

292 f weight reduction on vascular function with hyperinsulinemic patients deriving the greatest benefit.

293 During the hyperinsulinemic period, OLZ-ICV caused a decreased GIR,

294 tigate how severe hypoglycemia can be fatal, hyperinsulinemic, severe hypoglycemic (10-15 mg/dL) clam

295 l tangles, presently observed aberrations in hyperinsulinemic states may participate in linking insul

296 Conserved activation of hepatic aPKC in hyperinsulinemic states of T2DM, obesity and MetSyn is p

297 In hyperinsulinemic states, myocardin may act as a nuclear

298 or underlying this is dyslipidemia, which in hyperinsulinemic subjects with early type 2 diabetes is

299 se mice: mice with normal glucose tolerance, hyperinsulinemic yet glucose-tolerant mice, and prediabe

300 ry and biotelemetry in male Wistar and obese hyperinsulinemic Zucker diabetic fatty (ZDF) rats 45 min